Therapeutic treatment for VEGF related diseases

A method for treating Carpal tunnel syndrome, which comprises administering to a mammal in need of such treatment, a therapeutically effective amount of an inhibitor of the β isozyme of protein kinase C of the following formula

• wherein:
• W is —O—, —S—, —SO—, —SO2—, —CO—, C2-C6 alkylene, substituted alkylene, C2-C6 alkenylene, -aryl-, -aryl(CH2)mO—, -heterocycle-, -heterocycle-(CH2)mO—, -fused bicyclic-, -fused bicyclic-(CH2)mO—, —NR3—, —NOR3—, —CONH—, or —NHCO—;
• X and Y are independently C1-C4 alkylene, substituted alkylene, or together X, Y, and W combine to form —(CH2)n—AA—;
• R1s are hydrogen or up to four optional substituents independently selected from halo, C1-C4 alkyl, hydroxy, C1-C4 alkoxy, haloalkyl, nitro, NR4R5, or —NHCO(C1-C4 alkyl);
• R2 is hydrogen, CH3CO—, NH2, or hydroxy;
• R3 is hydrogen, (CH2)maryl, C1-C4 alkyl, —COO(C1-C4 alkyl), —CONR4R5, —(C═NH)NH2, —SO(C1-C4 alkyl), —SO2(NR4R5), or —SO2(C1-C4 alkyl);
• R4 and R5 are independently hydrogen, C1-C4 alkyl, phenyl, benzyl, or combine to the nitrogen to which they are bonded to form a saturated or unsaturated 5 or 6 member ring;
• AA is an amino acid residue;
• m is independently 0, 1, 2, or 3;
• and
• n is independently 2, 3, 4, or 5, or a pharmaceutically acceptable salt or ester thereof.